Abstract 179P
Background
The elderly have numerous risk factors, such as comorbidities, undernutrition, and sarcopenia. Therefore, they require careful treatment indications and management in cancer treatment. Body composition and sarcopenia assessment have been performed in gastric cancer preoperative patients to improve perioperative outcomes since 2018, and we have provided nutritional/rehabilitative assessments and medical support to eligible patients with collaborative practice (CP).
Methods
Of 881 patients with gastrectomy between January 2011 and April 2023, aged 80 years or older were included in this study. We compared the short-term perioperative outcomes of patients with preoperative nutritional/rehabilitative assessments and support with CP (supportive (S) group) and without this assessment (non-supportive (NS) group).
Results
Sixty patients in the S group and 103 in the NS group. There were no differences in age, gender, performance status, Charlson comorbidity index, clinical Stage, or preoperative nutritional assessment, but the S group had a higher body mass index (median; S: 22.2 mg/m2 vs. NS: 21.5 mg/m2, p=0.02) and higher ASA-PS (ASA-PS ≥3, S: 48.4 vs. NS: 24.8%, p=0.002). The S group had fewer total gastrectomies (S: 15.0% vs. NS: 29.1%, p=0.037) and more robotic/laparoscopic approaches (S: 75.0% vs. NS: 30.1%, p<0.001). There was no difference in operative time but less blood loss in the S group (S: 50ml vs. NS: 230ml, p<0.001). Overall complications were lower in the S group (S: 20.0% vs. NS: 36.9%, p=0.021), but there was no difference in Clavien-Dindo ≥3 or higher complications (S: 6.7% vs. NS: 12.6%, p=0.21). In particular, the S group had fewer surgical site infections (S: 6.7% vs. NS: 17.5%, p=0.041) and pneumonia (S: 3.3% vs. NS: 15.5%, p=0.009). Postoperative hospital stay was shorter in the S group (S: 11 days vs. NS: 16 days, p<0.001).
Conclusions
Our results suggest that pre-operative nutritional/rehabilitative assessments and support in elderly gastric cancer patients led to fewer postoperative infectious complications and shorter hospital stays.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sakai City Medical Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract